fd-1

Tegadifur (40497S) 是一种可口服的抗肿瘤化合物，具有抗新陈代谢作用，常与尿嘧啶林和治疗直肠腺癌。

DS18561882 是一种-可口服且具有选择性和高效性的亚甲基四氢叶酸脱氢酶 2 ( MTHFD2) 抑制剂，具有抗肿瘤活性，抑制 MTHFD1 的 活性，可用于研究乳腺癌。

FD 12-9, Anti-glioblastoma activity. is a flavonoid dimer, acts as a dual inhibitor of P-gp and BCRP, with EC50s of 285 nM and 0.9 nM, respectively.

TH9028, 作为MTHFD2抑制剂效力显著 (IC50= 11 nM)，在不同靶蛋白中表现出差异性选择性，其对hMTHFD2、MTHFD2L和MTHFD1的IC50值分别为7.97 nM、27 nM和0.5 nM。

FD1024是一种PIM抑制剂，对PIM1、PIM2和PIM3的IC50s分别为1.96、38.9及4.17 nM。用于急性髓系白血病研究的FD1024，对AML细胞系显示出显著的抗增殖效果，其对EOL-1、MV-4-11、KG-1和MOLM-16细胞的抑制浓度(IC50s)分别为0.16 μM、0.12 μM、1.05 μM和1.39 μM。此外，FD1024在小鼠模型中也表现出抗肿瘤活性。

Complement factor D-IN-1 is an effective and selective small-molecule reversible factor d inhibitor (IC50s: 0.006 and 0.05 μM in FD Thioesterolytic Fluorescent Assay and a MAC Deposition Assay, respectively).

FD-IN-1 is a factor D (FD) inhibitor with an IC50 of 12 nM.FD-IN-1 also inhibits factor XIa (FXIa) and Tryptase β2 with IC50s of 7.7 and 6.5μM, respectively. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system.

FD-211 is a δ lactone originally isolated from M. lutea with anticancer activity.1 It is cytotoxic to adriamycin-susceptible P388, T-24, HeLa, A549, and HL-60 cancer cells (IC50s = 4, 0.5, 1, 1, and 0.2 μg/ml, respectively), as well as adriamycin-resistant HL-60/ADR cells (IC50 = 0.1 μg/ml). FD-211 also inhibits DNA, RNA, and protein synthesis in HeLa cells (IC50 = 1.25 μg/ml for all). |1. Nozawa, O., Okazaki, T., Sakai, N., et al. A novel bioactive δ lactone FD-211. Taxonomy, isolation and characterization. J. Antibiot. (Tokyo) 48(2), 113-118 (1995).